Meeting
2015 ASCO Annual Meeting
PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.
Authors
Thomas Aparicio
Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Bobigny, France
Thomas Aparicio , Olivier Bouche Sr., Eric Francois , Emilie Maillard , Sylvie Kirscher , Julien Taïeb , Pierre-Luc Etienne , Roger Faroux , Faiza Khemissa , Farid El Hajbi , Christophe Locher , Yves Rinaldi , Thierry Lecomte , Sandrine Lavau-Denes , Mathieu Baconnier , Alice Oden-Gangloff , Dominique Genet , Elena Paillaud , Frederic Retornaz , Laurent Bedenne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01417494
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3541)
DOI
10.1200/jco.2015.33.15_suppl.3541
Abstract #
3541
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Bevacizumab combined with first-line chemotherapy in elderly patients (≥75 years old) with metastatic colorectal cancer: Final results of the noninterventional CASSIOPEE study.
First Author: Eric Francois
Poster
2020 Gastrointestinal Cancers Symposium
Treatment of metastatic colorectal cancer (mCRC) according to age.
First Author: Laura Ortega
Poster
2016 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
First Author: Kei Muro
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem